The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Activation of memory/effector T cells and association between prognosis and OX40-positive T cells in advanced head and neck cancer patients treated with anti-programmed death-1 antibody.
 
Hirofumi Ohmura
Speakers' Bureau - Chugai Pharma
 
Kyoko Yamaguchi
Speakers' Bureau - Ono Pharmaceutical
 
Fumiyasu Hanamura
Speakers' Bureau - Chugai Pharma
 
Tanoue Kenrou
Speakers' Bureau - Chugai Pharma
 
Shiho Kawagoe
No Relationships to Disclose
 
Kohei Arimizu
No Relationships to Disclose
 
Yuzo Matsushita
No Relationships to Disclose
 
Tatsuhiro Kajitani
No Relationships to Disclose
 
Shingo Tamura
Speakers' Bureau - Bayer Holding; Chugai Pharma; Eisai
 
Hozumi Shimokawa
No Relationships to Disclose
 
Keita Uchino
Honoraria - Kyowa Hakko Kirin
Speakers' Bureau - Asuka Seiyaku; Chugai Pharma; Ono Pharmaceutical
 
Hisanobu Oda
No Relationships to Disclose
 
Yudai Shinohara
No Relationships to Disclose
 
Mamoru Ito
No Relationships to Disclose
 
Kenji Tsuchihashi
Honoraria - Chugai Pharma
 
Taichi Isobe
Honoraria - Alexion Pharmaceuticals (I); Biogen (I); Novartis (I); Takeda (I)
 
Hiroshi Ariyama
No Relationships to Disclose
 
Hitoshi Kusaba
No Relationships to Disclose
 
Koichi Akashi
Consulting or Advisory Role - Kyowa Hakko Kirin; Sumitomo Group
Research Funding - Asahi Kasei; Astellas Pharma; Bristol-Myers Squibb; Celgene; Chugai Pharma; Kyowa Hakko Kirin; Shionogi
 
Eishi Baba
Honoraria - 3H Clinical Trial; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Medical Review Co., Ltd.; Merck Serono; Miyarisan Pharmaceutical; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Tsumura & Co.; Yakult Pharmaceutical
Research Funding - Astellas Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda